fda approves first oral glp-1 obesity drug august 1 2025 Medi-Cal coverage of weight loss drugs on chopping block under CA proposal Medi-Cal GLP-1 Weight Loss Medication

The Pharmacy Compounding Advisory Committee (PCAC) voted on Thursday 8-6 in favor of the move with one abstention

Two-tailed, unpaired Students t -tests were used to determine statistical significance in comparisons between two groups

These are investigational research applications, and no therapeutic efficacy in humans is implied by their study

In some parts of China (e.g., Keshan), the intake was only 314 g/day (56, 57), and the endemic Se deficiency appeared in the form of chronic osteochondropathy (KashinBeck disease) and chronic cardiomyopathy (Keshan disease), which are now preventable through Se supplementation (71, 72)

[DOI] [PMC free article] [PubMed] [Google Scholar] 171.Zhang Z, Yang J, Min Q, Ling C, Maiti D, Xu J, Qin L, Yang K